JP2017522261A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522261A5
JP2017522261A5 JP2016560702A JP2016560702A JP2017522261A5 JP 2017522261 A5 JP2017522261 A5 JP 2017522261A5 JP 2016560702 A JP2016560702 A JP 2016560702A JP 2016560702 A JP2016560702 A JP 2016560702A JP 2017522261 A5 JP2017522261 A5 JP 2017522261A5
Authority
JP
Japan
Prior art keywords
seq
sequence
variable region
chain variable
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522261A (ja
JP6805428B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2015/050433 external-priority patent/WO2015166484A1/en
Publication of JP2017522261A publication Critical patent/JP2017522261A/ja
Publication of JP2017522261A5 publication Critical patent/JP2017522261A5/ja
Application granted granted Critical
Publication of JP6805428B2 publication Critical patent/JP6805428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560702A 2014-04-27 2015-04-27 Ceacam1に対するヒト化抗体 Active JP6805428B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461984786P 2014-04-27 2014-04-27
US61/984,786 2014-04-27
US201562099155P 2015-01-01 2015-01-01
US62/099,155 2015-01-01
PCT/IL2015/050433 WO2015166484A1 (en) 2014-04-27 2015-04-27 Humanized antibodies against ceacam1

Publications (3)

Publication Number Publication Date
JP2017522261A JP2017522261A (ja) 2017-08-10
JP2017522261A5 true JP2017522261A5 (https=) 2018-05-17
JP6805428B2 JP6805428B2 (ja) 2021-01-06

Family

ID=54358258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560702A Active JP6805428B2 (ja) 2014-04-27 2015-04-27 Ceacam1に対するヒト化抗体

Country Status (24)

Country Link
US (2) US10550196B2 (https=)
EP (2) EP3766902A1 (https=)
JP (1) JP6805428B2 (https=)
KR (1) KR102452349B1 (https=)
CN (1) CN106573977B (https=)
AP (2) AP2016009504A0 (https=)
AU (1) AU2015254886A1 (https=)
BR (1) BR112016024972B1 (https=)
CA (1) CA2946262C (https=)
CL (1) CL2016002689A1 (https=)
CR (1) CR20160534A (https=)
DO (1) DOP2016000282A (https=)
EA (1) EA037613B1 (https=)
ES (1) ES2825080T3 (https=)
IL (1) IL248402B (https=)
MD (1) MD20160130A2 (https=)
MX (2) MX366359B (https=)
NI (1) NI201600162A (https=)
PE (1) PE20170764A1 (https=)
PH (1) PH12016502151A1 (https=)
PL (1) PL3137502T3 (https=)
SG (1) SG11201608772UA (https=)
SV (1) SV2016005307A (https=)
WO (1) WO2015166484A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CA3013443C (en) * 2016-02-01 2021-06-15 Eli Lilly And Company Parathyroid hormone - anti-rankl antibody fusion compounds
JP6993812B2 (ja) * 2016-08-17 2022-01-14 治範 小田 細胞傷害活性を向上させたリンパ球の培養方法及び該方法で得られた細胞傷害活性を向上させたリンパ球を含む細胞免疫治療剤
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
EP3601361A4 (en) * 2017-03-24 2020-12-16 Mogam Institute For Biomedical Research ANTI-CEACAM1 ANTIBODIES AND ITS USE
CN109663130B (zh) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
JP2022513729A (ja) * 2018-12-07 2022-02-09 ザ ブリガム アンド ウィメンズ ホスピタル,インコーポレイティド ヒト化及び親和性成熟抗ceacam1抗体
JP2022514615A (ja) * 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントCEACAM1(CD66a)に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof
US20220289819A1 (en) * 2019-11-07 2022-09-15 Green Cross Corporation Steric epitope of ceacam1, and anti-ceacam1 antibody, or fragment thereof, that specifically binds to same
EP3909601A1 (en) * 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
PE20251671A1 (es) 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
WO2024100663A1 (en) 2022-11-10 2024-05-16 Famewave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6022958A (en) 1986-08-13 2000-02-08 Bayer Corporation cDNAs coding for members of the carcinoembryonic antigen family
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
GB9421405D0 (en) 1994-10-21 1994-12-07 Dow Chemical Co Low voc laminating formulations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
DE19852804C1 (de) 1998-11-16 1999-12-23 Christoph Wagener Beeinflussung der Angiogenese durch CD66a
WO2001013937A1 (en) 1999-08-26 2001-03-01 Skubitz Keith M Peptides capable of modulating the function of cd66 (ceacam) family members
DE10016877A1 (de) 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
SE0002835D0 (sv) 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
WO2002068601A2 (en) 2001-02-28 2002-09-06 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
US20030022292A1 (en) 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20060058257A1 (en) 2001-08-03 2006-03-16 Christoph Wagener Influencing angiogenesis using CD66a
US20050107324A1 (en) 2003-07-12 2005-05-19 Bennett C. F. Modulation of CEACAM1 expression
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US20030190600A1 (en) 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
CN101658672B (zh) 2002-10-08 2017-09-26 免疫医疗公司 用iii类抗cea单克隆抗体和治疗剂进行联合治疗
CN101972478B (zh) 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
EP1682890A2 (en) 2003-11-13 2006-07-26 Genentech, Inc. Screening assays and methods of tumor treatment
CA2572289A1 (en) 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
US8735157B2 (en) 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
CA2633756C (en) 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
EP1988901B1 (en) 2006-02-27 2020-01-29 Gal Markel Ceacam based antibacterial agents
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009033095A2 (en) * 2007-09-07 2009-03-12 Cisthera, Incorporated Humanized pai-1 antibodies
WO2009141679A2 (en) 2007-11-05 2009-11-26 Gal Markel Ceacam1 based point-of-care cancer diagnostic
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
DK2424896T3 (en) * 2009-04-30 2015-12-14 Tel Hashomer Medical Res Infrastructure & Services Ltd The anti-CEACAM1 antibodies and methods of use thereof
CA2768725A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
BR112012003983A2 (pt) 2009-08-31 2021-09-14 Roche Glycart Ag Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção
ES2826883T3 (es) 2009-10-14 2021-05-19 Janssen Biotech Inc Métodos de maduración por afinidad de anticuerpos
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2785743B1 (en) * 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
PL2800196T3 (pl) 2011-12-27 2019-05-31 Lg Chemical Ltd Litowa bateria akumulatorowa i sposób jej wytwarzania
US20150337037A1 (en) * 2012-06-05 2015-11-26 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
KR102165464B1 (ko) * 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
WO2014055967A2 (en) * 2012-10-05 2014-04-10 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
CN104853776B (zh) 2012-10-12 2021-04-09 布里格姆及妇女医院股份有限公司 免疫应答的增强
ES2808684T3 (es) * 2013-11-25 2021-03-01 Famewave Ltd Composiciones que incluyen anticuerpos anti-ceacam1 y anti-pd para terapia de cáncer
WO2015075710A1 (en) * 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos

Similar Documents

Publication Publication Date Title
JP2017522261A5 (https=)
CN112771077B (zh) 针对cd3/cd20双特异性抗体的减轻细胞因子释放综合征的给药策略
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
KR102005308B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
JP2022046480A (ja) 癌治療におけるfgfr2阻害剤単独または免疫刺激剤との組み合わせ
CN105636986B (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
JP5380553B2 (ja) 放射性金属標識抗カドヘリン抗体
CA2946262C (en) Humanized antibodies against ceacam1
KR20200031645A (ko) 항cd8 항체 및 이의 용도
HRP20240338T1 (hr) Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
JP2019526622A5 (https=)
KR102380150B1 (ko) Gitr 항체, 방법, 및 용도
HRP20201090T1 (hr) Protutijela anti-icos
JP2017506067A5 (https=)
JP2018504610A5 (https=)
JP2013502913A5 (https=)
US9725518B2 (en) Antibodies that bind to Jagged 1
JP2021507877A5 (https=)
JP2012519492A5 (https=)
US12570757B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
CN116438199A (zh) 细胞定位特征和免疫疗法
KR20210065976A (ko) 종양 용해성 백시니아 바이러스와 면역 체크포인트 저해제의 병용에 의한 암 요법 그리고 이것에 사용하기 위한 의약 조성물 및 조합 의약
JP2020509995A (ja) 抗ヒトtim−3抗体およびその使用方法
CN118871467A (zh) 抗pd-l2抗体
WO2020104496A1 (en) Bispecific antibody targeting transferrin receptor 1 and soluble antigen